BAY U6751 hydrate

• 产品号: B3686
• CAS号: 114290-51-6(anhydrous)
• 分子式: C20H22ClNNa2O7
• 分子量: 469.82372
• 纯 度: ≥98% (HPLC)
• 保 存: protect from light

产品别名

• 标题: BAY U6751 hydrate
• IUPAC标准名: disodium 4-(2-chlorophenyl)-1-ethyl-6-methyl-5-[(propan-2-yloxy)carbonyl]-1,4-dihydropyridine-2,3-dicarboxylate hydrate
• IUPAC传统名: disodium 4-(2-chlorophenyl)-1-ethyl-5-(isopropoxycarbonyl)-6-methyl-4H-pyridine-2,3-dicarboxylate hydrate
• 别名: 4-(2-Chlorophenyl)-1-ethyl-1,4-dihydro-6-methyl-2,3,5-pyridinetricarboxylic acid 5-isopropyl ester disodium salt hydrate

产品登记号

• MDL号: MFCD08705410
• CAS号: 114290-51-6(anhydrous)
• PubChem SID: 24891730

产品性质

• Empirical Formula (Hill Notation): C20H20ClNNa2O6 · xH2O
• 纯度: ≥98% (HPLC)
• 外观: white solid
• 溶解度: H2O: >8 mg/mL
• GHS警示词: Warning
• GHS危险声明: H315-H319-H335
• 欧盟危险性物质标志: 刺激性(Irritant) (Xi)
• 个人保护装置: dust mask type N95 (US), Eyeshields, Gloves
• GHS警示性声明: P261-P305 + P351 + P338
• 危险公开号: 36/37/38
• 安全公开号: 26-36
• 保存条件: protect from light
• 保存温度: 2-8°C
• 德国WGK号: 3

产品详细信息

详细说明 (English)

Caution
Light sensitive. Store in amber vials.
Biochem/physiol Actions
BAY W1807, the active metabolite of BAY R3401, inhibits muscle glycogen phosphorylase a and b. In gel-filtered liver extracts, racemic BAY U6751 (containing active BAY W1807) was tested for inhibition of phosphorylase in the glycogenolytic (in which only phosphorylase a is active). In liver extracts, BAY U6751 (0.9-36 μmol/L) inhibited glycogen synthesis by phosphorylase b (notwithstanding the inclusion of AMP), but not by phosphorylase a. Inhibition of phosphorylase-a-catalyzed glycogenolysis was partially relieved by AMP (500 μmol/L). BAY U6751 facilitated phosphorylase-a dephosphorylation. Isolated hepatocytes and perfused livers were tested for BAY R3401-induced changes in phosphorylase-a:b ratios and glycogenolytic output.

详细说明 (简体中文)

Caution
Light sensitive. Store in amber vials.
Biochem/physiol Actions
BAY W1807, the active metabolite of BAY R3401, inhibits muscle glycogen phosphorylase a and b. In gel-filtered liver extracts, racemic BAY U6751 (containing active BAY W1807) was tested for inhibition of phosphorylase in the glycogenolytic (in which only phosphorylase a is active). In liver extracts, BAY U6751 (0.9-36 μmol/L) inhibited glycogen synthesis by phosphorylase b (notwithstanding the inclusion of AMP), but not by phosphorylase a. Inhibition of phosphorylase-a-catalyzed glycogenolysis was partially relieved by AMP (500 μmol/L). BAY U6751 facilitated phosphorylase-a dephosphorylation. Isolated hepatocytes and perfused livers were tested for BAY R3401-induced changes in phosphorylase-a:b ratios and glycogenolytic output.